| Medical and Health Sciences | 2021-2025 | 145 | IT 13 | 99.97 |
| Biological Sciences | 2021-2025 | 549 | IT 14 | 99.41 |
| Surgery | Lifetime | 359 | IT 13 | 99.69 |
| Gastroenterology | Lifetime | 39 | IT 2 | 99.57 |
| Genetics | Lifetime | 844 | IT 11 | 97.91 |
| Speech and Hearing | Lifetime | 610 | IT 11 | 91.93 |
| Surgery | 2021-2025 | 11 | IT 3 | 99.93 |
| Gastroenterology | 2021-2025 | 3 | IT 1 | 99.90 |
| Genetics | 2021-2025 | 34 | IT 2 | 99.36 |
| Epidemiology | 2021-2025 | 519 | IT 30 | 95.26 |
| Rheumatology | 2021-2025 | 179 | IT 16 | 95.45 |
| Immunology | 2021-2025 | 751 | IT 27 | 75.58 |
| Gastroesophageal reflux and treatments | Lifetime | 40 | IT 1 | 99.61 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 75 | IT 6 | 99.51 |
| Eosinophilic Esophagitis | Lifetime | 57 | IT 3 | 99.57 |
| Esophageal and GI Pathology | Lifetime | 120 | IT 6 | 99.46 |
| Dysphagia Assessment and Management | Lifetime | 86 | IT 3 | 98.64 |
| Inflammatory Bowel Disease | Lifetime | 208 | IT 13 | 98.95 |
| Microscopic Colitis | Lifetime | 198 | IT 18 | 98.84 |
| Eosinophilic Disorders and Syndromes | Lifetime | 215 | IT 24 | 98.23 |
| Gastrointestinal motility and disorders | Lifetime | 272 | IT 15 | 97.95 |
| Autoimmune and Inflammatory Disorders | Lifetime | 222 | IT 16 | 96.70 |
| Esophageal Cancer Research and Treatment | Lifetime | 789 | IT 24 | 96.31 |
| Systemic Sclerosis and Related Diseases | Lifetime | 989 | IT 130 | 94.15 |
| Celiac Disease Research and Management | Lifetime | 804 | IT 135 | 91.67 |
| Eosinophilic Esophagitis | 2021-2025 | 1 | IT 1 | 99.91 |
| Gastroesophageal reflux and treatments | 2021-2025 | 1 | IT 1 | 99.90 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 2 | IT 2 | 99.81 |
| Esophageal and GI Pathology | 2021-2025 | 11 | IT 2 | 99.63 |
| Dysphagia Assessment and Management | 2021-2025 | 14 | IT 2 | 98.62 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 16 | IT 2 | 99.20 |
| Inflammatory Bowel Disease | 2021-2025 | 50 | IT 5 | 99.40 |
| Microscopic Colitis | 2021-2025 | 35 | IT 5 | 99.41 |
| Gastrointestinal motility and disorders | 2021-2025 | 34 | IT 5 | 98.06 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 310 | IT 11 | 94.36 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 663 | IT 39 | 95.22 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 237 | IT 14 | 88.89 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 116 | IT 19 | 89.76 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 265 | IT 20 | 87.87 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 185 | IT 9 | 86.07 |
| Digestive system and related health | 2021-2025 | 183 | IT 11 | 81.67 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 747 | IT 85 | 85.41 |
| Celiac Disease Research and Management | 2021-2025 | 227 | IT 43 | 85.85 |
| Respiratory and Cough-Related Research | 2021-2025 | 497 | IT 64 | 84.93 |
| Pregnancy and Medication Impact | 2021-2025 | 521 | IT 24 | 81.21 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 967 | IT 59 | 77.80 |
| Liver Diseases and Immunity | 2021-2025 | 909 | IT 80 | 76.90 |
| Congenital gastrointestinal and neural anomalies | 2021-2025 | 665 | IT 38 | 53.02 |
| Therapeutic Uses of Natural Elements | 2021-2025 | 590 | IT 77 | 41.46 |
